Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema.
Health Technology Assessment Unit, Ente di Supporto Tecnico Amministrativo Regionale, Regional Health Service, 50100 Firenze, Italy.
Andrea
A
Messori
D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab; D003930:Diabetic Retinopathy; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema; D056687:Off-Label Use; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab